Why IMU is a multi multi bagger, page-12513

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing ONCOLYTIC VIRUS drugs?
• How many ONCOLYTIC VIRUS drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of ONCOLYTIC VIRUS?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the ONCOLYTIC VIRUS therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for ONCOLYTIC VIRUS and their status?
• What are the key designations that have been granted to the emerging and approved drugs?

Key Players

• Genelux Corporation
• Candel Therapeutics
• CG Oncolgy
• DNAtrix
• SillaJen Biotherapeutics
• Oncolytics Biotech
• Wuhan Binhui Biotechnology
• Oryx GmbH
• Jiangsu Sinorda Biomedicine Co., Ltd
• Virogin Biotech
• Replimune
• Viralytics
• Oncolys Biopharma
• Istari Oncology
• Immvira Pharma
• Seneca Therapeutics
• Treovir, LLC
• Targovax
• Lokon Pharma
• ORCA Therapeutics
• Beijing SyngenTech
• ViruCure
• Tasly Pharmaceuticals
• Turnstone Biologics
• BioInvent
• Transgene
• Elicera Therapeutics
• Orgenesis
• Virttu Biologics
• Imugene
• Astellas Pharma
• Wuhan Binhui Biotechnology Co., Ltd.
• Mustang Bio
• Virogin Biotech
• Vaxiion Therapeutics
• ImmVirX
• Memgen
• Replimune
• Immvira Pharma
• ViroCure
• GeneMedicine
• PsiOxus Therapeutics
• VCN Biosciences
• Candel therapeutics
• Sorrento Therapeutics
• Imugene Limited
• Calidi Biotherapeutics
• Replimune
• TILT Biotherapeutics
• Guangzhou Virotech Pharmaceutical
• DNAtrix
• Oncorus
• BioEclipse Therapeutics